Synonyms: MRT2359
Compound class:
Synthetic organic
Comment: MRT-2359 is a GSPT1 (a.k.a. eRF3a)-targeting molecular glue degrader. It uses a cereblon (CRBN) binding moiety to induce degradation of the translation termination factor GSPT1 (GSPT1; P15170), This mechanism produces an anti-proliferative effect on cancer cells. MRT-2359's chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.
|
|
No information available. |
Summary of Clinical Use |
MRT-2359 has advanced to clinical evaluation, for efficacy against advanced solid tumours. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | Phase 1/Phase 2 Interventional | Monte Rosa Therapeutics, Inc |